Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Artificial intelligence (AI)-aided analysis of pathology slides showed potential as a predictive biomarker for non-small cell ...

Pembrolizumab is under clinical development by Merck and currently in Phase II for Anal Cancer. According to GlobalData, Phase II drugs for Anal Cancer have a 19% phase transition success rate (PTSR) ...

Pembrolizumab is under clinical development by Merck and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 32% phase ...

Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.

Other companies with checkpoint inhibitors on the market also have HCC in its sights, including Merck KGaA/Pfizer whose Bavencio (avelumab) PD-L1 inhibitor is in phase II testing in this indication.

Complex diseases could require complex biomarkers for accurate diagnosis in the years ahead, according to a leading ...

who won yesterday test match The commercialization of PD-L1 products is just around the corner. Alphamab Oncology's performance on the Hong Kong Stock Exchange boosts market confidence The number of ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...